Laura Biganzoli
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
Risi E, Di Leo A, Biganzoli L, Sotiriou C, Vitale S, Boccalini G, Romagnoli D, Huober J, Di Cosimo S, Hilbers F, Guarducci C, Bonechi M, McCartney A, Migliaccio I, Benelli M, Biagioni C, Malorni L. An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Ther Adv Med Oncol 2019; 11:1758835919891608.
11.12.2019An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
11.12.2019Ther Adv Med Oncol 2019; 11:1758835919891608
Risi Emanuela, Di Leo Angelo, Biganzoli Laura, Sotiriou Christos, Vitale Stefania, Boccalini Giulia, Romagnoli Dario, Huober Jens, Di Cosimo Serena, Hilbers Florentine, Guarducci Cristina, Bonechi Martina, McCartney Amelia, Migliaccio Ilenia, Benelli Matteo, Biagioni Chiara, Malorni Luca
ASCO 2009: What's New in Breast Cancer Therapy?
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's New in Breast Cancer Therapy?. Breast Care (Basel) 2009; 4:268-271.
14.08.2009ASCO 2009: What's New in Breast Cancer Therapy?
14.08.2009Breast Care (Basel) 2009; 4:268-271
Biganzoli Laura, Bonnefoi Hervé, Cardoso Fatima, Coleman Robert, Thürlimann Beat